Watch RANI. Know when insiders buy.
One email the day a filing lands. Free.
RANI
Rani Therapeutics Holdings, Inc.
0.76
+0.01 +1.34%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM $4.9M +306.4%NET INCOME −$30.1MNET DEBT $8.9M52W 0.46 – 2.85SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.7M | — | — | −$8.8M | −$7.4M | — | -0.04 | −$9M | $32K | −$9.1M | Aug 13 |
| Q1 2026 · Mar 31 | $1.7M | +893.0% | — | −$8.3M | −$7M | — | -0.04 | −$6.5M | $15K | −$6.5M | May 15 |
| Q4 2025 · Dec 31derived | $1.5M | +42.1% | — | −$8.5M | −$10.3M | — | 0.05 | $294K | $0 | $294K | Mar 26 |
| Q3 2025 · Sep 30 | $0 | — | — | −$7.3M | −$5.4M | — | -0.12 | −$5.1M | $0 | −$5.1M | Nov 6 |
| Q2 2025 · Jun 30 | $0 | — | — | −$10.5M | −$6.7M | — | -0.18 | −$5.8M | $37K | −$5.8M | Aug 13 |
| Q1 2025 · Mar 31 | $172K | — | — | −$12M | −$7.3M | — | -0.22 | −$8.1M | $51K | −$8.2M | May 15 |
| Q4 2024 · Dec 31derived | $1M | — | — | −$15M | −$8.9M | — | -0.27 | −$8.7M | $31K | −$8.7M | Mar 26 |
| Q3 2024 · Sep 30 | $0 | — | — | −$11.8M | −$6.8M | — | -0.24 | −$8.4M | $125K | −$8.5M | Nov 6 |
| Q2 2024 · Jun 30 | $0 | — | — | −$12.5M | −$6.8M | — | -0.26 | −$9M | $94K | −$9.1M | Aug 7 |
| Q1 2024 · Mar 31 | $0 | — | — | −$14M | −$7.5M | — | -0.29 | −$9.4M | $18K | −$9.4M | May 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$13.4M | −$7.1M | — | -0.27 | −$12.5M | $167K | −$12.6M | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$17.9M | −$9.2M | — | -0.36 | −$14.3M | $479K | −$14.8M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.6M | — | −$38.3M | −$29.7M | -1817.1% | -0.45 | −$18.7M | $88K | −$18.8M | — | — |
| FY2024 · to Dec 31 | $1M | — | −$53.3M | −$30M | -2920.0% | -1.05 | −$35.5M | $268K | −$35.8M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$66.1M | −$34M | — | -1.33 | −$51.2M | $1.2M | −$52.5M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$63.5M | −$30.6M | — | -1.28 | −$46.5M | $1.6M | −$48.1M | — | — |
| FY2021 · to Dec 31 | $2.7M | — | −$51.6M | −$8.3M | -306.6% | -0.43 | −$32.2M | $506K | −$32.8M | — | — |
| FY2020 · to Dec 31 | $462K | — | −$16.5M | −$16.7M | -3615.4% | — | −$15M | $1.2M | −$16.2M | — | — |
Every number comes from Rani Therapeutics Holdings, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.